In addition, accumulated data regarding the effectiveness of anti-IgE treatments in recent trials (e.g., immunoadsorption of IgE [62,63,64], combined the use of omalizumab and immunoadsorption of IgE [65], and a double-blind, placebo-controlled randomized clinical trial of omalizumab in pediatric AD patients [66]) confirm the importance of IgE allergy in the pathogenesis of AD [1,60,61]. The gene discussed is IGHE; the disease is allergic disease.